Core Viewpoint - The stock of Sino Biopharmaceutical-B (02591) has experienced a significant decline of over 25% following its inclusion in the Hong Kong Stock Connect, with a current trading price of HKD 32.9 and a trading volume of HKD 19.69 million [1] Group 1: Stock Performance - Sino Biopharmaceutical-B's stock fell more than 14% after being included in the Hong Kong Stock Connect and has continued to decline, with a total drop of 25% [1] - As of the latest update, the stock is down 12.73% at HKD 32.9, with a trading volume of HKD 19.69 million [1] Group 2: Regulatory Changes - The Shanghai and Shenzhen Stock Exchanges announced adjustments to the constituent stocks of the Hang Seng Composite MidCap Index, resulting in the inclusion of Sino Biopharmaceutical in the Hong Kong Stock Connect, effective from December 8, 2025 [1] Group 3: Product Development - Sino Biopharmaceutical announced that its self-developed long-acting GLP-1 receptor agonist, Ispaglutide α (Yinuo Qing®), has been officially included in the National Medical Insurance Drug List for 2025, set to take effect on January 1, 2026 [1] - Ispaglutide α (Yinuo Qing®) is recognized as a domestically produced long-acting GLP-1 receptor agonist [1]
港股异动 | 银诺医药-B(02591)早盘再跌超12% “入通”后累计跌幅达25%